Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Diluted Average) (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $93.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.82% to $93.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.0 million, a 2.82% increase, with the full-year FY2024 number at $90.3 million, up 22.37% from a year prior.
  • Shares Outstanding (Diluted Average) was $93.0 million for Q3 2025 at Caribou Biosciences, roughly flat from $93.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $93.0 million in Q2 2025 to a low of $10.3 million in Q2 2021.
  • A 5-year average of $69.5 million and a median of $67.6 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 492.08% in 2022, then grew 1.06% in 2023.
  • Caribou Biosciences' Shares Outstanding (Diluted Average) stood at $31.7 million in 2021, then soared by 92.02% to $60.8 million in 2022, then increased by 21.39% to $73.8 million in 2023, then increased by 22.37% to $90.3 million in 2024, then grew by 2.97% to $93.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Shares Outstanding (Diluted Average) are $93.0 million (Q3 2025), $93.0 million (Q2 2025), and $92.7 million (Q1 2025).